Our in vivo findings demonstrated that FCBP effectively mitigates weight gain in a dose-dependent manner and reduces inflammatory markers (ICAM-1 and VCAM-1) in endothelial cells, suggesting its role in managing diet-induced obesity and preventing early atherosclerosis. The gene discussed is ICAM1; the disease is obesity due to melanocortin 4 receptor deficiency.